Horst Domdey
Vorstandsvorsitzender bei BioM AG Munich BioTech Development
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Lars Ullerich | M | - |
HP Health Solutions Germany GmbH
HP Health Solutions Germany GmbH Miscellaneous Commercial ServicesCommercial Services GNA Biosolutions GmbH develops instruments for molecular pathogen detection. The firm offers PCA technology, lab and portable solutions. The company was founded by Joachim Stehr, Federico Bürsgens and Lars Ullerich in 2010 and is headquartered in Martinsried, Germany. | 14 Jahre |
Frederico Bürsgens | M | - |
HP Health Solutions Germany GmbH
HP Health Solutions Germany GmbH Miscellaneous Commercial ServicesCommercial Services GNA Biosolutions GmbH develops instruments for molecular pathogen detection. The firm offers PCA technology, lab and portable solutions. The company was founded by Joachim Stehr, Federico Bürsgens and Lars Ullerich in 2010 and is headquartered in Martinsried, Germany. | 1 Jahre |
Joachim Stehr | M | - |
HP Health Solutions Germany GmbH
HP Health Solutions Germany GmbH Miscellaneous Commercial ServicesCommercial Services GNA Biosolutions GmbH develops instruments for molecular pathogen detection. The firm offers PCA technology, lab and portable solutions. The company was founded by Joachim Stehr, Federico Bürsgens and Lars Ullerich in 2010 and is headquartered in Martinsried, Germany. | 1 Jahre |
Bernhard Wimmer | M | - |
BioM AG Munich BioTech Development
BioM AG Munich BioTech Development Investment ManagersFinance BioM AG Munich BioTech Development (BMBD) is a venture capital firm specialized in the life sciences sector. Located in Martinsried on the outskirts of Munich, BMBD was established in 2002 to manage the investment portfolio of BioM AG, a regional technology transfer and venture capital services company. BioM was created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition, and provides business support services to Munich-based biotechnology companies, focusing on start-ups. BMBD manages the BioM Venture Capital fund. Their clients include regional banks, German and European private equity firms and private individuals. The firm operates in partnership with public entities, in particular the German Federal Ministry of Education and Research (BMBF) and HighTech Gründerfonds (HTGF), a partnership between the Government of Germany, the KfW banking group and leading technology corporations.
BioM Biotech Cluster Development GmbH
BioM Biotech Cluster Development GmbH Medical DistributorsDistribution Services BioM AG is a regional technology transfer and venture capital services company created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition. The firm provides business support services to Munich-based biotechnology companies, focusing on startups. Through BioM Biotech Cluster Development GmbH, established in 2006, BioM coordinates the Munich Biotech Cluster, with the objective of turning it into a leading biotechnology center in Europe. They seek to foster an active cooperation between Bavarian research institutions and corporations. BioM actively invests seed capital in biotechnology startups in the Munich area, and manages a venture capital investment fund invested in high-growth early-stage businesses. | 18 Jahre |
Maike Sander | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Bärbel Brumme-Bothe | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Petra Burgstaller | M | - |
BioM AG Munich BioTech Development
BioM AG Munich BioTech Development Investment ManagersFinance BioM AG Munich BioTech Development (BMBD) is a venture capital firm specialized in the life sciences sector. Located in Martinsried on the outskirts of Munich, BMBD was established in 2002 to manage the investment portfolio of BioM AG, a regional technology transfer and venture capital services company. BioM was created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition, and provides business support services to Munich-based biotechnology companies, focusing on start-ups. BMBD manages the BioM Venture Capital fund. Their clients include regional banks, German and European private equity firms and private individuals. The firm operates in partnership with public entities, in particular the German Federal Ministry of Education and Research (BMBF) and HighTech Gründerfonds (HTGF), a partnership between the Government of Germany, the KfW banking group and leading technology corporations. | 17 Jahre |
Christina Enke-Stolle | F | - |
BioM AG Munich BioTech Development
BioM AG Munich BioTech Development Investment ManagersFinance BioM AG Munich BioTech Development (BMBD) is a venture capital firm specialized in the life sciences sector. Located in Martinsried on the outskirts of Munich, BMBD was established in 2002 to manage the investment portfolio of BioM AG, a regional technology transfer and venture capital services company. BioM was created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition, and provides business support services to Munich-based biotechnology companies, focusing on start-ups. BMBD manages the BioM Venture Capital fund. Their clients include regional banks, German and European private equity firms and private individuals. The firm operates in partnership with public entities, in particular the German Federal Ministry of Education and Research (BMBF) and HighTech Gründerfonds (HTGF), a partnership between the Government of Germany, the KfW banking group and leading technology corporations. | 15 Jahre |
Jutta Koch-Unterseher | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Heike Wolke | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Jana Wolf | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Claus Scheidereit | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Annette Grüters-Kieslich | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Sabine Kunst | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Hannah Monyer | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Alt Peter-André | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Patrick Cramer | M | 55 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Jan Grapentin | M | - |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Björn Ragnar Björnsson | M | 78 | 1 Jahre | |
Anders Lundin | M | 60 | 2 Jahre | |
Alf Gunnar Martin Nicklasson | M | 69 | - | |
Jan Lundberg | M | 78 | - | |
Hans Liljeblad | M | 67 | - | |
Joel-Tomas Citron | M | 62 | 4 Jahre | |
Lars Bergkvist | M | 60 | 4 Jahre | |
Peter Jan Sture Ström | M | 72 | - | |
Weine Nejdemo | M | 76 | 5 Jahre | |
Mikael Asp | M | 62 | 3 Jahre | |
Ingela Hägglund | M | 60 | - | |
Claes Piehl | M | 74 | 6 Jahre | |
Alexander Kotsinas | M | 57 | 6 Jahre | |
Enno Spillner | M | 55 |
BioM AG Munich BioTech Development
BioM AG Munich BioTech Development Investment ManagersFinance BioM AG Munich BioTech Development (BMBD) is a venture capital firm specialized in the life sciences sector. Located in Martinsried on the outskirts of Munich, BMBD was established in 2002 to manage the investment portfolio of BioM AG, a regional technology transfer and venture capital services company. BioM was created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition, and provides business support services to Munich-based biotechnology companies, focusing on start-ups. BMBD manages the BioM Venture Capital fund. Their clients include regional banks, German and European private equity firms and private individuals. The firm operates in partnership with public entities, in particular the German Federal Ministry of Education and Research (BMBF) and HighTech Gründerfonds (HTGF), a partnership between the Government of Germany, the KfW banking group and leading technology corporations. | - |
Boris Mannhardt | M | - |
BioM AG Munich BioTech Development
BioM AG Munich BioTech Development Investment ManagersFinance BioM AG Munich BioTech Development (BMBD) is a venture capital firm specialized in the life sciences sector. Located in Martinsried on the outskirts of Munich, BMBD was established in 2002 to manage the investment portfolio of BioM AG, a regional technology transfer and venture capital services company. BioM was created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition, and provides business support services to Munich-based biotechnology companies, focusing on start-ups. BMBD manages the BioM Venture Capital fund. Their clients include regional banks, German and European private equity firms and private individuals. The firm operates in partnership with public entities, in particular the German Federal Ministry of Education and Research (BMBF) and HighTech Gründerfonds (HTGF), a partnership between the Government of Germany, the KfW banking group and leading technology corporations. | 4 Jahre |
Anders O. Lönner | M | 79 | 1 Jahre | |
Mikael Widell | M | 66 | - | |
Lars Olsson | M | - | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 20 | 55,56% |
Schweden | 16 | 44,44% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Horst Domdey
- Persönliches Netzwerk